These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465 [TBL] [Abstract][Full Text] [Related]
23. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia]. Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125 [TBL] [Abstract][Full Text] [Related]
24. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft. Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557 [TBL] [Abstract][Full Text] [Related]
25. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up. Juckett M; Rowlings P; Hessner M; Keever-Taylor C; Burns W; Camitta B; Casper J; Drobyski WR; Hanson G; Horowitz M; Lawton C; Margolis J; Peitryga D; Vesole D Bone Marrow Transplant; 1998 May; 21(9):893-9. PubMed ID: 9613781 [TBL] [Abstract][Full Text] [Related]
26. Matched-pair analysis of peripheral blood stem cells compared to marrow for allogeneic transplantation. Lickliter JD; McGlave PB; DeFor TE; Miller JS; Ramsay NK; Verfaillie CM; Burns LJ; Wagner JE; Eastlund T; Dusenbery K; Weisdorf DJ Bone Marrow Transplant; 2000 Oct; 26(7):723-8. PubMed ID: 11042652 [TBL] [Abstract][Full Text] [Related]
27. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience. Lamparelli T; Van Lint MT; Gualandi F; Occhini D; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Ferrara GB; Delfino L; Pozzi S; Morabito A; Zikos P; Vitale V; Corvo R; Frassoni F; Bacigalupo A Bone Marrow Transplant; 1997 Dec; 20(12):1057-62. PubMed ID: 9466278 [TBL] [Abstract][Full Text] [Related]
28. Addition of ATG to the conditioning regimen is a major determinant for outcome after transplantation with partially lymphocyte-depleted grafts from voluntary unrelated donors. Schattenberg A; van der Meer A; Preijers F; Schaap N; Rinkes M; van der Maazen R; Allebes W; Joosten I; De Witte T Bone Marrow Transplant; 2004 Jun; 33(11):1115-21. PubMed ID: 15064694 [TBL] [Abstract][Full Text] [Related]
29. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft. Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494 [TBL] [Abstract][Full Text] [Related]
30. Allogeneic matched T-cell-depleted bone marrow transplantation for acute leukemia patients. Aristei C; Aversa F; Raymondi C; Marsella AR; Panizza BM; Perrucci E; Piro F; Maranzano E; Lupattelli M; Martelli MF; Latini P Cancer J Sci Am; 1996; 2(6):330-4. PubMed ID: 9166553 [TBL] [Abstract][Full Text] [Related]
31. Allogeneic bone marrow transplantation for children with histiocytic disorders: use of TBI and omission of etoposide in the conditioning regimen. Hale GA; Bowman LC; Woodard JP; Cunningham JM; Benaim E; Horwitz EM; Heslop HE; Krance RA; Leung W; Shearer PD; Handgretinger R Bone Marrow Transplant; 2003 Jun; 31(11):981-6. PubMed ID: 12774048 [TBL] [Abstract][Full Text] [Related]
32. [Allogeneic bone marrow transplantation in children from related donors other than HLA-identical siblings]. Morimoto T; Hattori K; Yabe H; Yabe M; Hinohara T; Shimizu T; Matsumoto M; Hagihara M; Tsuji K; Kato S Rinsho Ketsueki; 1998 Sep; 39(9):631-9. PubMed ID: 9796395 [TBL] [Abstract][Full Text] [Related]
34. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659 [TBL] [Abstract][Full Text] [Related]
35. Bone marrow transplantation from matched related donors for patients with Fanconi anemia using low-dose busulfan and cyclophosphamide as conditioning. Torjemane L; Ladeb S; Ben Othman T; Abdelkefi A; Lakhal A; Ben Abdeladhim A Pediatr Blood Cancer; 2006 Apr; 46(4):496-500. PubMed ID: 16333862 [TBL] [Abstract][Full Text] [Related]
36. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Kebriaei P; Kline J; Stock W; Kasza K; Le Beau MM; Larson RA; van Besien K Bone Marrow Transplant; 2005 May; 35(10):965-70. PubMed ID: 15806131 [TBL] [Abstract][Full Text] [Related]
37. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens. Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Ball E; Cook D; Andresen S; Kuczkowski E; Bolwell B Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282 [TBL] [Abstract][Full Text] [Related]
38. Allogeneic hematopoietic cell transplantation from alternative donors in children with myelodysplastic syndrome: is that an alternative? Kalwak K; Wójcik D; Gorczyńska E; Toporski J; Turkiewicz D; Slociak M; Ussowicz M; Pajdosz K; Socha P; Chybicka A Transplant Proc; 2004 Jun; 36(5):1574-7. PubMed ID: 15251388 [TBL] [Abstract][Full Text] [Related]
39. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome. Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447 [TBL] [Abstract][Full Text] [Related]
40. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation. Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]